专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US09458447B2 MPHOSPH1 peptides and vaccines including the same 有权
标题翻译： MPHOSPH1肽和疫苗包括相同
公开(公告)号：US09458447B2
公开(公告)日：2016-10-04
申请号：US14131019
申请日：2012-08-09
申请人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura
IPC分类号： C07K7/00 , A61K38/10 , C12N9/00 , A61K39/00 , C07K14/47 , C12N9/14 , G01N33/50 , C12N5/0784 , C12N5/10 , G01N33/574 , A61K38/00
CPC分类号： C12N9/93 , A61K38/00 , A61K39/00 , A61K39/0011 , C07K14/4738 , C12N5/0639 , C12N5/10 , C12N9/14 , C12N2502/1114 , C12Y306/04004 , G01N33/505 , G01N33/57407 , G01N2440/14
摘要： As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.
摘要翻译：如本文更详细讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。本发明的肽包括上述提供的MPHOSPH1衍生的氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰形式保持必需的CTL诱导性原始序列。还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物或组合物。本发明的肽，多核苷酸和药物或组合物在癌症和肿瘤的治疗和预防中的任一个或两者中都具有特别的用途，包括例如膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌症，胃癌，NSCLC，淋巴瘤，骨肉瘤，前列腺癌，肾癌和软组织肿瘤。

62. 发明授权

US09119800B2 HIG2 and URLC10 epitope peptide and vaccines containing the same 有权
标题翻译： HIG2和URLC10表位肽和含有它们的疫苗
公开(公告)号：US09119800B2
公开(公告)日：2015-09-01
申请号：US13059618
申请日：2009-08-14
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K39/385 , A61K39/00 , C07K14/725 , A61K38/00
CPC分类号： A61K39/0011 , A61K38/00 , C07K14/7051
摘要： The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.
摘要翻译：本发明提供了含有一种或多种具有SEQ ID NO：1或2的氨基酸序列的肽的一种或多种肽或一种或多种编码用于治疗和/或预防受试者的癌症的肽的多核苷酸的药剂或组合物其HLA-A抗原为HLA-A0206。此外，本发明提供使用这些肽，多核苷酸或药剂诱导CTL和抗原呈递细胞的方法。

63. 发明授权

US09056890B2 WDHD1 peptides and vaccines including the same 有权
标题翻译： WDHD1肽和疫苗包括相同
公开(公告)号：US09056890B2
公开(公告)日：2015-06-16
申请号：US13880442
申请日：2011-10-20
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K38/00 , C07K7/06 , C07K14/47 , A61K39/00
CPC分类号： C07K7/06 , A61K38/00 , A61K39/0011 , C07K14/47
摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：32的分离的表位肽或免疫原性片段。感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。还提供了包括这些肽的药物组合物和治疗癌症的方法。

64. 发明申请

US20140162952A1 ERAP1-DERIVED PEPTIDE AND USE THEREOF 有权
标题翻译： ERAP1衍生的肽及其用途
公开(公告)号：US20140162952A1
公开(公告)日：2014-06-12
申请号：US14235666
申请日：2012-07-27
申请人： Toyomasa Katagiri , Takuya Tsunoda
发明人： Toyomasa Katagiri , Takuya Tsunoda
IPC分类号： C07K14/47 , A61K31/138 , A61K38/17
CPC分类号： C07K14/4705 , A61K31/138 , A61K38/00 , A61K38/1709 , C12N9/485 , G01N33/5011 , G01N33/57484 , G01N2333/4704 , G01N2333/95 , G01N2500/02
摘要： Provided is a novel cancer-treating agent which can be used as a novel choice for the treatment of cancer. Specifically provided are: a peptide that inhibits binding of ERAP1 polypeptide to PHB2 polypeptide, which comprises a binding site of the ERAP1 polypeptide to the PHB2 polypeptide, and a pharmaceutical composition comprising the peptide. In addition, provided is a method for screening a drug candidate for treating and/or preventing cancer using inhibition of the binding of the ERAP1 polypeptide to PP1α polypeptide, PKA polypeptide or PKB polypeptide as an index.
摘要翻译：提供了可用作治疗癌症的新型选择的新型癌症治疗剂。具体提供的是：抑制ERAP1多肽与包含ERAP1多肽与PHB2多肽的结合位点的PHB2多肽的结合的肽和包含该肽的药物组合物。此外，提供了通过抑制ERAP1多肽与PP1α多肽，PKA多肽或PKB多肽的结合作为指标来筛选用于治疗和/或预防癌症的候选药物的方法。

65. 发明授权

US08697631B2 TMEM22 peptides and vaccines including the same 失效
标题翻译： TMEM22肽和疫苗包括它们
公开(公告)号：US08697631B2
公开(公告)日：2014-04-15
申请号：US13515656
申请日：2010-12-13
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： C07K7/06 , A61K38/08 , G01N33/53
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , A61K2039/57 , C07K14/705
摘要： Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.
摘要翻译：描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段这里。本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

66. 发明授权

US08674069B2 MELK epitope peptides and vaccines containing the same 有权
标题翻译： MELK表位肽和含有它们的疫苗
公开(公告)号：US08674069B2
公开(公告)日：2014-03-18
申请号：US13056598
申请日：2009-07-30
申请人： Takuya Tsunoda , Ryuji Ohsawa
发明人： Takuya Tsunoda , Ryuji Ohsawa
IPC分类号： C07K5/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K7/06 , C07K14/4747 , C12N5/0638 , C12N9/12 , C12N2502/11 , C12N2510/00 , C12Y207/10002 , C12Y207/11001
摘要： According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
摘要翻译：根据本发明，具有SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽被证明具有细胞毒性T淋巴细胞（CTL）诱导性。因此，本发明提供了具有选自SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽。肽可以包括一个，两个或几个氨基酸取代，缺失，插入或添加，只要其CTL诱导性得以保留即可。此外，本发明提供了用于治疗和/或预防癌症的药物和/或预防其术后复发，其含有任何这些肽。本发明的药剂包括疫苗。

67. 发明申请

US20140023671A1 TOMM34 PEPTIDES AND VACCINES INCLUDING THE SAME 有权
标题翻译： TOMM34肽和疫苗，包括它们
公开(公告)号：US20140023671A1
公开(公告)日：2014-01-23
申请号：US13990766
申请日：2011-11-25
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
IPC分类号： A61K39/00 , C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , C07K14/705 , C12N5/0638 , C12N2501/998 , C12N2502/1114 , C12N2502/1121 , G01N33/57407
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
摘要翻译：本发明提供分离的肽或衍生自SEQ ID NO：42的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。本发明还提供包含这些肽的药物组合物。本发明的肽可用于治疗癌症。

68. 发明申请

US20130224234A1 TTLL4 PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： TTLL4肽和含有它的疫苗
公开(公告)号：US20130224234A1
公开(公告)日：2013-08-29
申请号：US13820736
申请日：2011-09-06
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa
IPC分类号： C12N9/00 , C07K16/40
CPC分类号： C12N9/93 , A61K39/0011 , C07K14/4748 , C07K16/40
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTLL4 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from TTLL4 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTLL4, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的TTLL4基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供含有衍生自TTLL4的肽或编码多肽作为活性成分的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤的方法免疫，使用衍生自TTLL4的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

69. 发明授权

US08455444B2 CDH3 peptide and medicinal agent comprising the same 有权
标题翻译： CDH3肽和包含其的药剂
公开(公告)号：US08455444B2
公开(公告)日：2013-06-04
申请号：US12673451
申请日：2008-06-05
申请人： Yasuharu Nishimura , Katsunori Imai , Takuya Tsunoda , Yusuke Nakamura
发明人： Yasuharu Nishimura , Katsunori Imai , Takuya Tsunoda , Yusuke Nakamura
IPC分类号： A61K38/00 , C07K7/00
CPC分类号： A61K31/7088 , A61K38/00 , A61K39/0011 , C07K14/705
摘要： The present invention provides a peptide of the following (A) or (B): (A) a peptide including an amino acid sequence of SEQ ID NO: 1 or 2; (B) a peptide including an amino acid sequence of SEQ ID NO 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide has an activity to induce killer T cells.
摘要翻译：本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1或2的氨基酸序列的肽; （B）包含SEQ ID NO 1或2的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或加入，并且其中所述肽具有活性诱导杀伤T细胞。

70. 发明授权

US08420329B2 Methods for diagnosing or treating prostate cancer 失效
标题翻译：诊断或治疗前列腺癌的方法
公开(公告)号：US08420329B2
公开(公告)日：2013-04-16
申请号：US13130284
申请日：2009-11-18
申请人： Yusuke Nakamura , Hidewaki Nakagawa , Takuya Tsunoda
发明人： Yusuke Nakamura , Hidewaki Nakagawa , Takuya Tsunoda
IPC分类号： G01N33/53
CPC分类号： C12Q1/6886 , C12N15/1136 , C12N2310/14 , C12N2310/531 , C12Q2600/112 , C12Q2600/136 , G01N33/57434 , G01N2500/04
摘要： The present invention provides methods for detecting and/or diagnosing cancer through the determination of the expression level of the STC2 gene. The gene was discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer, methods for treating cancer. Moreover, the present invention provides double-stranded molecules targeting the STC2 gene, which are suggested to be useful in the treatment of cancer. The compositions and methods of the present invention find particular applicability to prostate cancer, more specifically, castration-resistant prostate cancer and aggressive prostate cancer.
摘要翻译：本发明提供了通过确定STC2基因的表达水平来检测和/或诊断癌症的方法。发现该基因能够将癌细胞与正常细胞区分开来。此外，本发明提供筛选用于治疗癌症的治疗剂的方法，用于治疗癌症的方法。此外，本发明提供靶向STC2基因的双链分子，其被认为可用于治疗癌症。本发明的组合物和方法特别适用于前列腺癌，更具体地说，抗阉割抗性前列腺癌和侵袭性前列腺癌。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式